Olema Oncology

Olema Oncology

生物技术研究

San Francisco,California 8,312 位关注者

关于我们

Olema Oncology is a cancer medicines company dedicated to impacting breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a differentiated oral medicine known as a complete estrogen receptor antagonist (CERAN) initially in development for metastatic breast cancer. Our pipeline also includes OP-3136, a potent, selective oral inhibitor of the KAT6 pathway. At Olema, we are building a focused team committed to our mission with intention and clarity. Working alongside a talented, passionate group of leaders and advisors, we strive to create better medicines that aim to help patients feel better, longer. For more information, visit us at www.olema.com.

网站
https://olema.com
所属行业
生物技术研究
规模
51-200 人
总部
San Francisco,California
类型
上市公司
创立
2007
领域
pharmaceuticals、biotechnology、drug development、oncology、breast cancer、nuclear receptors和small molecules

地点

  • 主要

    780 Brannan St

    US,California,San Francisco,94103

    获取路线
  • 101 Rogers St

    3B

    US,Massachusetts,Cambridge,02142

    获取路线

Olema Oncology员工

动态

相似主页

查看职位